Brief: Aldeyra Therapeutics Completes Enrollment In Phase 3 Clinical Trial Of Reproxalap In Dry Eye Disease
13/06/2024 12:45
June 13 (Reuters) - Aldeyra Therapeutics Inc ALDX.O :
* ALDEYRA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 3
CLINICAL
TRIAL OF REPROXALAP IN DRY EYE DISEASE
* ALDEYRA THERAPEUTICS INC: CLINICAL TRIAL RESULTS AND
POTENTIAL
NEW DRUG APPLICATION RESUBMISSION EXPECTED IN SECOND HALF OF
2024
Source text for Eikon: ID:nBw3hgWrFa
Further company coverage: ALDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease
Aldeyra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aldeyra Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora